Studies have predicted repression of NIS and increased iodine metabolism in RAI-refractory metastatic disease.10,11 Selumetinib, a selective inhibitor of MEK1 and MEK2, and dabrafenib, a selective potent BRAFV600E inhibitor, had induced radioactive iodine uptake in a subset of patients with RAI-refractory disease and retreatment with RAI.44,45. The gene discussed is MAP2K1; the disease is metastatic neoplasm.